Prescription drug · ANDA
Aripiprazole NDC 66689-735
Aripiprazole 1 mg/mL · Solution · Oral · VistaPharm, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 66689-735-05 | 66689073505 | 1 BOTTLE in 1 CARTON (66689-735-05) / 150 mL in 1 BOTTLEMarketed from Jun 19, 2020 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Aripiprazole
- Generic name (nonproprietary)
- aripiprazole
- Active ingredients
- Aripiprazole — 1 mg/mL
- Dosage form
- Solution
- Route
- Oral
- Labeler
- VistaPharm, LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 212870
- Marketing start
- Listing expires
- Identifiers
- Product ID 66689-735_87f75d68-e1b9-4ddc-a2ac-2398bf1b4619SPL ID 87f75d68-e1b9-4ddc-a2ac-2398bf1b4619SPL set ID 06529caf-698f-41da-81ec-d0ba5ab200d7RxCUI 485496UNII 82VFR53I78UPC 0366689735054
- Pharmacologic class
- Atypical Antipsychotic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N466689073505followed by a unit qualifier and the quantityPackage 66689-0735-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia [see CLINICAL STUDIES (14.1) ] Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see CLINICAL STUDIES (14.2) ] Adjunctive Treatment of Major Depressive Disorder [see CLINICAL STUDIES (14.3) ] Irritability Associated with Autistic Disorder [see CLINICAL STUDIES (14.4 ) ] Treatment of Tourette’s Disorder [see CLINICAL STUDIES (14.5) ] Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia (14.1) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I (14.2) Adjunctive Treatment of Major Depressive Disorder ( 14.3 ) Irritability Assoc…
Excerpt only. Read the full label for complete information.